Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Alvarez

Interventional Cardiology San Antonio, TX Medical Doctor

NPI 1821183559 CMS profile 83251

4411 Medical Dr Ste 300, Ste 120, San Antonio, TX 78229

Open in the dashboard

General payments

$62,742

1,230 records reported · program years 2019–2025

Research payments

$31

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,541,532 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jorge Alvarez of San Antonio, TX is reported in the CMS Open Payments database as having received $62,742 across 1,230 general payments and $31 in research payments paid to them. Separately, studies naming them as principal investigator received $1,541,532 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,587 169
2024 General $9,361 222
2024 Research $31 1
2023 General $5,083 190
2022 General $8,052 154
2021 General $23,490 185
2020 General $7,015 118
2019 General $3,154 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Alvarez
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jorge Alvarez were reported at $6,587. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jorge Alvarez Interventional Cardiology median Middle half National median
2019 $3,154 $1,097 $329–$3,048 $163
2020 $7,015 $473 $161–$1,480 $114
2021 $23,490 $677 $233–$1,827 $132
2022 $8,052 $978 $333–$2,724 $149
2023 $5,083 $1,136 $382–$2,986 $160
2024 $9,361 $1,181 $395–$3,326 $164
2025 $6,587 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $22,297 97 payments
  2. Medtronic, Inc. $20,335 369 payments
  3. Medtronic Vascular, Inc. $6,966 124 payments
  4. Abiomed $1,389 59 payments
  5. Novartis Pharmaceuticals Corporation $1,364 95 payments
  6. Abbott Laboratories $1,095 27 payments
  7. AstraZeneca Pharmaceuticals LP $1,055 58 payments
  8. Merck Sharp & Dohme Corporation $765 47 payments
  9. Pfizer Inc. $722 66 payments
  10. Edwards Lifesciences Corporation $601 4 payments
  11. Other $6,154 284 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,125 24 payments
  2. Food and Beverage $23,463 1,195 payments
  3. Consulting Fee $2,758 4 payments
  4. Travel and Lodging $1,001 3 payments
  5. Long term medical supply or device loan $282 1 payment
  6. Education $113 3 payments
Products named General payments · program years 2019–2025
  1. XARELTO $22,297 97 payments
  2. COREVALVE EVOLUT R $16,259 315 payments
  3. CoreValve Evolut Transcatheter Valve Systems $6,950 123 payments
  4. CoreValve Evolut Transcatheter Valve Systems $3,927 50 payments
  5. Impella $1,221 49 payments
  6. VERQUVO $940 59 payments
  7. ELIQUIS $675 59 payments
  8. BRILINTA $635 36 payments
  9. LEQVIO $511 38 payments
  10. ENTRESTO $502 34 payments
  11. Other $9,107 406 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $31 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

5,331

Median for Interventional Cardiology: 2,236

Drug cost

$862,239

Median for Interventional Cardiology: $380,412

Branded share of claims

32.8%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 291 $271,716
Xarelto Rivaroxaban Brand 122 $148,242
Entresto Sacubitril/Valsartan Brand 110 $127,586
Farxiga Dapagliflozin Propanediol Brand 69 $66,015
Brilinta Ticagrelor Brand 39 $40,366
Ozempic Semaglutide Brand 27 $25,204
Edarbi Azilsartan Medoxomil Brand 53 $23,315
Edarbyclor Azilsartan Med/Chlorthalidone Brand 43 $23,255
Repatha Sureclick Evolocumab Brand 14 $19,324
Multaq Dronedarone Hcl Brand 21 $16,408

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$640,666

Medicare's payments for the services billed

Medicare patients

2,182

Average age 76

Services billed

8,275

1,050 women, 1,132 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 50%
Diabetes 44%
Chronic kidney disease 42%
Heart failure 41%
Atrial fibrillation 39%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
$213 110 —
XARELTO
$195 122 —
VERQUVO
$175 — —
LEQVIO
$145 — —
CAMZYOS
$145 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

1,231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record